|
3-AP and Cytarabine in Treating Patients With Hematologic Cancer Clinical Trials Facts presented on Clinical Trials Search isn't designed to be a substitute for proven healthcare advice, calls or treatment using a real mD. We aren't mDs. Always confer with your physician on 3-AP and Cytarabine in Treating Patients With Hematologic Cancer conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. 3-AP and Cytarabine in Treating Patients With Hematologic Cancer Clinical research trials and 3-AP and Cytarabine in Treating Patients With Hematologic Cancer healthcare trials happen in a lot of of localities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / undertakings is to answer particular human medical questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, such as 3-AP and Cytarabine in Treating Patients With Hematologic Cancer. 3-AP and Cytarabine in Treating Patients With Hematologic Cancer Clinical Trials and other clinical trials allow volunteers to get healthcare treatment alternatives before they are available to the general public. Most times the participants receive treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a 3-AP and Cytarabine in Treating Patients With Hematologic Cancer clinical trial. Human subjects often receive the most effective healthcare possible for their 3-AP and Cytarabine in Treating Patients With Hematologic Cancer condition. Risks are a reality, nonetheless, and may include more or frequent dr. calls, healthcare hazards (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "3" Clinical Trials Conditions > 3-AP and Cytarabine in Treating Patients With Hematologic Cancer  3-AP and Cytarabine in Treating Patients With Hematologic Cancer
3-AP and Cytarabine in Treating Patients With Hematologic Cancer
For Condition: atypical chronic myeloid leukemia,acute leukemia,chronic leukemia,myelodysplastic and myeloproliferative disease
Status: Recruiting
Sponsor(s): Vion Pharmaceuticals ,
Synopsis: RATIONALE: Drugs used in chemotherapy such as cytarabine use different ways to stop cancer cells from dividing so they stop growing or die. 3-AP may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth and may help cytarabine kill more cancer cells by making them more sensitive to the drug. PURPOSE: Phase I trial to study the effectiveness of combining cytarabine with 3-AP in treating patients who have relapsed or refractoryhematologic cancer.
Details: OBJECTIVES: - Determine the feasibility, tolerability, and toxic effects of 3-AP in combination with cytarabine in patients with hematologic malignancies. - Determine the maximum tolerated dose and phase II dose of cytarabine in this regimen in these patients. - Determine the biological effects of 3-AP and its interaction with cytarabine in these patients. OUTLINE: This is a pilot, dose-escalation study of cytarabine. Patients receive 3-AP IV over 6 hours followed by cytarabine IV over 18 hours on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients achieving a response may receive an additional course as consolidation therapy. Cohorts of 3-6 patients receive escalating doses of cytarabine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, an additional 10 patients receive treatment at that dose. PROJECTED ACCRUAL: Approximately 20-25 patients will be accrued for this study.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Diagnosis of 1 of the following hematologic malignancies: - Acute myeloid leukemia - Acute lymphoblastic leukemia - Chronic myelogenous leukemia (CML) - CML in blast crisis - Chronic lymphocytic leukemia - High-risk* myelodysplastic syndromes, including the following: - Refractory anemia with excess blasts (RAEB) - RAEB in transformation - Chronic myelomonocytic leukemia NOTE: *High-risk myelodysplasia defined as having an International Performance Scoring System score of at least 1.5, based on adverse cytogenetics, greater than 10% blasts in marrow, and cytopenias in at least 2 lineages - Relapsed or refractory disease - Ineligible for higher priority protocols PATIENT CHARACTERISTICS: Age - 18 and over Performance status - ECOG 0-2 Life expectancy - More than 2 months Hematopoietic - See Disease Characteristics Hepatic - Bilirubin no greater than 2.0 mg/dL (unless considered due to malignancy) - ALT or AST no greater than 3 times upper limit of normal - Chronic hepatitis allowed Renal - Creatinine no greater than 2.0 mg/dL (unless considered due to malignancy) Cardiovascular - No myocardial infarction within the past 3 months - No symptomatic coronary artery disease - No arrhythmias (other than atrial fibrillation or flutter) requiring treatment - No uncontrolled congestive heart failure Other - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - Concurrent infections under active treatment with and controlled by antibiotics allowed - No other concurrent life-threatening illness - No mental deficit or psychiatric history that would preclude giving informed consent or complying with protocol PRIOR CONCURRENT THERAPY: Biologic therapy - At least 1 week since prior growth factors, including the following: - Epoetin alfa - Filgrastim (G-CSF) - Sargramostim (GM-CSF) - Interleukin-3 - Interleukin-11 - No concurrent anticancer immunotherapy Chemotherapy - At least 72 hours since prior hydroxyurea - Recovered from prior chemotherapy - No other concurrent anticancer chemotherapy Endocrine therapy - Not specified Radiotherapy - At least 2 weeks since prior radiotherapy - No concurrent anticancer radiotherapy Surgery - Not specified Other - At least 3 weeks since prior myelosuppressive cytotoxic agents (in the absence of rapidly progressing disease) - At least 1 week since prior nonmyelosuppressive therapy - No other concurrent standard or investigational therapy for the malignancy
Total Enrollment:
Location and Contact Information:
Overall Study Official:
MarioSznol, Study Chair, Vion Pharmaceuticals
University of Texas - MD Anderson Cancer Center *Recruiting*
Houston, Texas, 77030-4095
United States
Recruiting Francis Giles 713-792-7305
Additional Information:
Study ID Numbers: CDR0000306465; MDA-DM-030096,VION-CLI-032
Study Start Date:
Record last reviewed: June 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00064090
Other Atypical Chronic Myeloid Leukemia Studies:
1. Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
2. Umbilical Cord Blood Transplantation in Treating Patients With Severe Aplastic Anemia, Malignant Thymoma, or Myelodysplasia
3. Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome
4. MS-275 in Treating Patients With Hematologic Cancer
5. VNP40101M and Hydroxyurea in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplasia
Related Studies:
Other atypical chronic myeloid leukemia Clinical Trials
Other Texas Clinical Trials
Other Houston Clinical Trials
3-AP and Cytarabine in Treating Patients With Hematologic Cancer
|
|
|
|
|
|
|
|
